Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CODXNASDAQ:ELGXNASDAQ:IDXGNASDAQ:NVCN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCODXCo-Diagnostics$0.29+0.3%$0.30$0.23▼$2.23$9.30M0.6250,744 shs384,882 shsELGXEndologix$0.07$0.03$0.22▼$7.10$1.41M0.731.28 million shs85,372 shsIDXGInterpace Biosciences$0.77+0.6%$8.06$2.57▼$10.42$3.40M0.766,816 shs5,002 shsNVCNNeovasc$30.03$29.69$4.59▼$30.07$82.28M1.756,993 shs1 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCODXCo-Diagnostics0.00%+9.33%-5.65%-7.60%-77.58%ELGXEndologix0.00%0.00%0.00%0.00%0.00%IDXGInterpace Biosciences0.00%+3.27%-12.51%-14.29%-31.26%NVCNNeovasc0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCODXCo-Diagnostics3.7094 of 5 stars3.55.00.04.40.00.01.3ELGXEndologixN/AN/AN/AN/AN/AN/AN/AN/AIDXGInterpace BiosciencesN/AN/AN/AN/AN/AN/AN/AN/ANVCNNeovascN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCODXCo-Diagnostics 3.00Buy$5.501,816.38% UpsideELGXEndologix 0.00N/AN/AN/AIDXGInterpace Biosciences 0.00N/AN/AN/ANVCNNeovasc 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest CODX, ELGX, NVCN, and IDXG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/28/2025CODXCo-DiagnosticsD Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/28/2025CODXCo-DiagnosticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$10.00(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCODXCo-Diagnostics$3.71M2.60N/AN/A$1.70 per share0.17ELGXEndologix$143.37M0.01N/AN/A$3.56 per share0.02IDXGInterpace Biosciences$40.21M0.08$0.39 per share1.99($14.16) per share-0.05NVCNNeovasc$3.81M21.60N/AN/A$5.77 per share5.20Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCODXCo-Diagnostics-$37.64M-$1.17N/AN/AN/A-1,025.45%-60.16%-52.69%8/6/2025 (Estimated)ELGXEndologix-$64.76M-$2.19N/AN/AN/A-44.65%-63.96%-13.26%N/AIDXGInterpace Biosciences$800KN/A0.00∞N/A10.39%-8.09%37.14%N/ANVCNNeovasc-$41.20M-$15.08N/A∞N/A-1,082.92%-127.25%-80.31%N/ALatest CODX, ELGX, NVCN, and IDXG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025CODXCo-Diagnostics-$0.33-$0.24+$0.09-$0.24$0.38 million$0.05 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCODXCo-DiagnosticsN/AN/AN/AN/AN/AELGXEndologixN/AN/AN/AN/AN/AIDXGInterpace BiosciencesN/AN/AN/AN/AN/ANVCNNeovascN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCODXCo-DiagnosticsN/A4.434.23ELGXEndologix0.290.390.28IDXGInterpace BiosciencesN/A0.590.59NVCNNeovasc0.802.962.85Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCODXCo-Diagnostics14.99%ELGXEndologix51.61%IDXGInterpace Biosciences5.73%NVCNNeovasc1.64%Insider OwnershipCompanyInsider OwnershipCODXCo-Diagnostics8.40%ELGXEndologix1.30%IDXGInterpace Biosciences5.50%NVCNNeovascN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCODXCo-Diagnostics10033.57 million30.75 millionOptionableELGXEndologix52819.17 millionN/AOptionableIDXGInterpace Biosciences1524.41 million4.17 millionNot OptionableNVCNNeovasc492.74 millionN/ANot OptionableCODX, ELGX, NVCN, and IDXG HeadlinesRecent News About These CompaniesTop Small-Cap Stocks for May 2023 - InvestopediaMay 13, 2023 | news.google.comNFDA accepts application for Roche's Vabysmo for the - GlobeNewswireMay 9, 2023 | news.google.comNNew treatment option opens avenues in geographic atrophy - HealioMay 8, 2023 | news.google.comNPachychoroid neovasculopathy has clinical properties that differ ... - Nature.comMay 8, 2023 | news.google.comNThe NOD audit provides data and insights for the management for ... - Modern RetinaMay 8, 2023 | news.google.comNShockwave Medical Reports First Quarter 2023 Financial Results - GlobeNewswireMay 8, 2023 | news.google.comNHeart valve repair and replacement devices market size to grow by ... - BenzingaMay 5, 2023 | news.google.comNASCRS: Prediction of imminent conversion to neovascular AMD ... - Optometry TimesMay 5, 2023 | news.google.comNFaricimab in Treatment-Resistant nARMD | OPTH - Dove Medical PressMay 4, 2023 | news.google.comNRestoring vision through retinal ganglion cell repopulation - Ophthalmology Times EuropeMay 4, 2023 | news.google.comNSTAR Trial: Surgery Not Superior to Pneumatic Displacement for ... - MD MagazineMay 4, 2023 | news.google.comNThe NOD audit: Insights into the current state of management for ... - Nature.comMay 4, 2023 | news.google.comNOn the horizon: Treatments for both forms of AMD - Ophthalmology Times EuropeMay 3, 2023 | news.google.comNBiosimilar Ranibizumab Displays Comparable Safety, Efficacy to ... - The Center for BiosimilarsApril 28, 2023 | news.google.comNReal World Evidence Supporting GA Therapy Management Strategies - AJMC.com Managed Markets NetworkApril 28, 2023 | news.google.comNLow-vision services improve vision, quality of life in patients with ... - HealioApril 28, 2023 | news.google.comNNew Vabysmo data suggest greater retinal drying versus aflibercept ... - GlobeNewswireApril 25, 2023 | news.google.comNNew treatment tackles both forms of AMD - Ophthalmology TimesApril 25, 2023 | news.google.comNPrice Variation in Economic Evaluations of Infliximab Could ... - The Center for BiosimilarsApril 25, 2023 | news.google.comN1-Year Outcomes of Phase 3 Study for SB15, Proposed biosimilar to Eylea (aflibercept), Presented at the 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting - Yahoo FinanceApril 25, 2023 | news.google.comNNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCODX, ELGX, NVCN, and IDXG Company DescriptionsCo-Diagnostics NASDAQ:CODX$0.29 +0.00 (+0.35%) Closing price 07/3/2025 03:47 PM EasternExtended Trading$0.28 0.00 (-1.39%) As of 07/3/2025 04:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.Endologix NASDAQ:ELGXEndologix, Inc. develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. The company offers minimally-invasive endovascular aneurysm repair (EVAR), including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the Ovation abdominal stent graft system. It also provides endovascular aneurysm sealing system (EVAS) product that is based on the Nellix EVAS system to seal the aneurysm, and provides blood flow to the legs through two blood lumens. In addition, the company offers proximal aortic extensions and limb extensions, which allow physicians to customize the implant to fit the patient's anatomy; and accessories to facilitate the delivery of its EVAR and EVAS products, including compatible guidewires, inflation devices, and snares. It sells its products through direct sales force, and a network of third party distributors and agents. The company was formerly known as Radiance Medical Systems, Inc. and changed its name to Endologix, Inc. in May 2002. Endologix, Inc. was founded in 1992 and is headquartered in Irvine, California.Interpace Biosciences NASDAQ:IDXGInterpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.Neovasc NASDAQ:NVCNNeovasc, Inc. engages in the development, manufacture and marketing of medical devices. It focuses on Neovast Tiara and Neovasc Reducer products. The company was founded on November 2, 2000 and is headquartered in Richmond, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Correction Equals Opportunity in Domino’s Pizza Stock Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
